Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services logo
$245.60 -0.37 (-0.15%)
Closing price 08/28/2025 03:59 PM Eastern
Extended Trading
$244.95 -0.65 (-0.26%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings
Sell
0
Hold
2
Buy
7

Based on 9 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 2 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for WST.

Consensus Price Target

$320.71
30.59% Upside
According to the 9 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $320.71. The highest price target for WST is $400.00, while the lowest price target for WST is $245.00. The average price target represents a forecasted upside of 30.59% from the current price of $245.60.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Analyst Ratings Over Time

TypeCurrent Forecast
8/29/24 to 8/29/25		1 Month Ago
7/30/24 to 7/30/25		3 Months Ago
5/31/24 to 5/31/25		1 Year Ago
8/30/23 to 8/29/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$320.71$320.71$332.50$442.75
Forecasted Upside30.59% Upside28.56% Upside57.79% Upside40.65% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

West Pharmaceutical Services Stock vs. The Competition

TypeWest Pharmaceutical ServicesMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside30.59% Upside15,720.89% Upside10.25% Upside
News Sentiment Rating
Positive News

See Recent WST News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/25/2025UBS Group
3 of 5 stars		John Sourbeer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$285.00 ➝ $320.00+19.29%
7/25/2025Evercore ISI
3 of 5 stars		Daniel Markowitz
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$275.00 ➝ $350.00+33.17%
6/24/2025Barclays
3 of 5 stars		Luke Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageEqual Weight$245.00+12.88%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy
4/21/2025Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Etoch
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeStrong-Buy
2/14/2025KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Paul Knight
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetOverweight ➝ Overweight$470.00 ➝ $325.00+46.46%
2/14/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$250.00+25.38%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$350.00 ➝ $355.00+8.95%
12/13/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Schenkel
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoveragePeer Perform
2/7/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$323.00 ➝ $536.00+34.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:41 AM ET.


Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 28, 2025. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • West Pharmaceutical Services, Inc. has a solid market capitalization of approximately $17.66 billion, reflecting its strong position in the medical instruments sector.
  • The current stock price is around $320, which is supported by positive analyst ratings, including several "buy" recommendations, suggesting potential for growth.
  • The company has a low debt-to-equity ratio, indicating a strong balance sheet and financial stability, which can be attractive to risk-averse investors.
  • West Pharmaceutical Services, Inc. has consistently increased its dividend, with a recent boost to $0.22 per share, demonstrating a commitment to returning value to shareholders.

West Pharmaceutical Services
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

  • The stock has a relatively high price-to-earnings ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • The PEG ratio is elevated, suggesting that the stock's price may not be justified by its expected earnings growth, which could deter value-focused investors.
  • Despite recent revenue growth, the company's net margin is moderate, which may raise concerns about profitability in a competitive market.
  • Market volatility, as indicated by a beta of 1.05, suggests that the stock may experience fluctuations that could impact short-term investors.
  • Analysts have mixed ratings, with some holding a "hold" position, indicating uncertainty about the stock's future performance.

WST Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $320.71, with a high forecast of $400.00 and a low forecast of $245.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 2 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WST shares.

According to analysts, West Pharmaceutical Services's stock has a predicted upside of 30.59% based on their 12-month stock forecasts.

West Pharmaceutical Services has been rated by research analysts at Barclays, Evercore ISI, and UBS Group in the past 90 days.

Analysts like West Pharmaceutical Services more than other "medical" companies. The consensus rating score for West Pharmaceutical Services is 2.89 while the average consensus rating score for "medical" companies is 2.78. Learn more on how WST compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:WST) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel